Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on February 13, 2026, Oppenheimer upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Perform to Outperform. Analyst Price Forecast Suggests 14.51% Upside As of February 4, 2026, the average one-year price target for Vertex Pharmaceuticals is $532.50/share. The forecasts range from a low of $360.99 to a high of $656.25. The average … Read more